An All-Human Hepatic System, TruVivo® Distinguishes Between Marketed Human Hepatotoxicants and Non-Hepatotoxicants

Toni Steiner, Heather Sexton, Jennifer Pratt, Michele Wich, Haley Roeder, Kevin Johnson, Edward LeCluyse¹ and David Thompson Inotiv, Maryland Heights, MO 63043 and ¹LifeNet Health, Research Triangle Park, NC 27709

Background and Purpose: 

Many in vitro models for hepatotoxicity have been explored over the past decade including novel alternative methods (NAMs) such as hepatic spheroids, organoids and liver-on-chip models. While these platforms provide improved physiological models of the tissue, they are often limited by throughput cost and the need for specialized equipment. While initially used for drug metabolism and PK modeling, hepatocyte cocultures have reemerged as useful models for studying pharmacological pathways, generation of in vitro disease models, and investigative tools for hepatotoxicity. In this study we utilized TruVivo®, an all-human hepatocyte co-culture system, to see if it could distinguish between approved drugs that were removed from the market for hepatotoxicity and their non-hepatotoxic analogs.